词条 | Green Cross (South Korea) |
释义 |
| name = GC Pharma(Green Cross Corporation) {{lang|ko|(주)녹십자}} | foundation = October 5, 1967 | location = Yongin, South Korea | key_people = Eun Chul Huh (President) | services = Manufacturing and sales of biotheapeutics. | homepage = http://www.greencross.co.kr http://www.greencross.com/eng/main.do }} GC Pharma [Green Cross Corporation] ({{kse|006280}}) is a biopharmaceutical company headquartered in Yongin, South Korea. GC Pharma specializes in the development and commercialization of vaccines, protein therapies, and therapeutic antibodies for use in the fields of oncology and infectious disease. GC Pharma was established as "Sudo Microorganism Medical Supplies Co." in 1967, and changed the name to "Green Cross" in 1971. The company is engaged in research, development, manufacturing and sales of biotherapeutics, including plasma proteins, recombinant antibodies, and vaccines. Green Cross developed "Hepavax B", the world’s third hepatitis B vaccine, in 1983, the world's first vaccine “Hantavax” against epidemic hemorrhagic fever in 1988, the world’s second varicella vaccine in 1995, "Greengene", the world’s 4th recombinant antihemophilic drug, and the world's second treatment of Hunter syndrome “Hunterase” in 2012. As part of GC Pharma's global strategies, there are three operations based in the overseas as of 2016.
Products
References1. ^Greencross.com, "History" 6 : Pharmaceutical companies of South Korea|Companies listed on the Korea Exchange|Pharmaceutical companies established in 1967|Health care companies of South Korea|Vaccine producers|South Korean brands |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。